Determination of nafronyl in pharmaceutical preparations by means of stopped-flow micellar-stabilized room temperature phosphorescence. 1998

A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
Department of Analytical Chemistry, University of Extremadura, Badajoz, Spain.

The stopped-flow mixing technique was applied to micellar-stabilized room temperature phosphorimetry by measuring the fast appearance of the phosphorescent signal yielded by nafronyl in the presence of sodium dodecyl sulfate and thallium nitrate. This mixing system diminishes the time required for the deoxygenation of micellar medium by sodium sulfite, allowing a kinetic curve that levels off within only 5 s to be obtained. Phosphorescence enhancers thallium(I) nitrate, sodium dodecyl sulfate and sodium sulfite were optimized to obtain maximum sensitivity and selectivity. A pH value of 10.5 was selected as adequate for phosphorescence development. Two rapid, straightforward and automatic methods were proposed using the slope and amplitude of the kinetic curve, which are directly proportional to the nafronyl concentration, as analytical parameters. Calibration graphs were linear for the concentration range from 30 to 600 ng ml-1. Praxilene, the only commercial formulation containing nafronyl, was analysed by both proposed methodologies. Suitable recovery values were obtained.

UI MeSH Term Description Entries
D008163 Luminescent Measurements Techniques used for determining the values of photometric parameters of light resulting from LUMINESCENCE. Bioluminescence Measurements,Bioluminescent Assays,Bioluminescent Measurements,Chemiluminescence Measurements,Chemiluminescent Assays,Chemiluminescent Measurements,Chemoluminescence Measurements,Luminescence Measurements,Luminescent Assays,Luminescent Techniques,Phosphorescence Measurements,Phosphorescent Assays,Phosphorescent Measurements,Assay, Bioluminescent,Assay, Chemiluminescent,Assay, Luminescent,Assay, Phosphorescent,Assays, Bioluminescent,Assays, Chemiluminescent,Assays, Luminescent,Assays, Phosphorescent,Bioluminescence Measurement,Bioluminescent Assay,Bioluminescent Measurement,Chemiluminescence Measurement,Chemiluminescent Assay,Chemiluminescent Measurement,Chemoluminescence Measurement,Luminescence Measurement,Luminescent Assay,Luminescent Measurement,Luminescent Technique,Measurement, Bioluminescence,Measurement, Bioluminescent,Measurement, Chemiluminescence,Measurement, Chemiluminescent,Measurement, Chemoluminescence,Measurement, Luminescence,Measurement, Luminescent,Measurement, Phosphorescence,Measurement, Phosphorescent,Measurements, Bioluminescence,Measurements, Bioluminescent,Measurements, Chemiluminescence,Measurements, Chemiluminescent,Measurements, Chemoluminescence,Measurements, Luminescence,Measurements, Luminescent,Measurements, Phosphorescence,Measurements, Phosphorescent,Phosphorescence Measurement,Phosphorescent Assay,Phosphorescent Measurement,Technique, Luminescent,Techniques, Luminescent
D009257 Nafronyl A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors. Nafronyloxalate,Naftidrofuryl,Artocoron,Azunaftil,Di-Actane,Dusodril,Gévatran,LS-121,Nafronyl Oxalate,Nafti Von Ct,Nafti-Puren,Nafti-Ratiopharm,Naftifurin Oxalate,Naftilong,Naftilux,Praxilene,Praxilène,Di Actane,LS 121,LS121,Nafti Puren,Nafti Ratiopharm,NaftiRatiopharm,Oxalate, Nafronyl,Oxalate, Naftifurin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D015813 Substance Abuse Detection Detection of drugs that have been abused, overused, or misused, including legal and illegal drugs. Urine screening is the usual method of detection. Drug Abuse Testing,Illicit Drug Testing,Street Drug Testing,Substance Abuse Testing,Drug Abuse Detection,Drug Abuse Screening,Illicit Drug Detection,Street Drug Detection,Detection, Drug Abuse,Detection, Illicit Drug,Detection, Street Drug,Detection, Substance Abuse,Detections, Drug Abuse,Detections, Illicit Drug,Detections, Street Drug,Detections, Substance Abuse,Drug Abuse Detections,Drug Abuse Screenings,Drug Abuse Testings,Drug Testing, Illicit,Drug Testings, Illicit,Illicit Drug Detections,Illicit Drug Testings,Screening, Drug Abuse,Screenings, Drug Abuse,Street Drug Detections,Street Drug Testings,Substance Abuse Detections,Substance Abuse Testings,Testing, Drug Abuse,Testing, Illicit Drug,Testing, Street Drug,Testing, Substance Abuse,Testings, Drug Abuse,Testings, Illicit Drug,Testings, Street Drug,Testings, Substance Abuse

Related Publications

A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
January 2003, Analytical biochemistry,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
October 1994, Talanta,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
December 1985, Analytical chemistry,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
July 1996, Talanta,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
November 2002, Journal of pharmaceutical and biomedical analysis,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
January 2007, Luminescence : the journal of biological and chemical luminescence,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
April 2005, Guang pu xue yu guang pu fen xi = Guang pu,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
May 1983, Journal of pharmaceutical sciences,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
January 1989, Journal of pharmaceutical and biomedical analysis,
A Munoz de la Peña, and A Espinosa Mansilla, and J A Murillo Pulgarín, and A Alañón Molina, and P Fernández López
April 1988, The Analyst,
Copied contents to your clipboard!